Mangalam Drugs loan defaults: ₹15.57 crore overdue in 2026

Disclosure highlights

Mangalam Drugs and Organics Limited has disclosed that it has defaulted on loan obligations to Bank of Maharashtra and Bank of Baroda for a period exceeding 30 days. The company said the disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which requires listed entities to report debt defaults beyond the 30-day threshold. The overdue amounts relate to cash credit facilities with the two banks. The start dates of default for both facilities fall in October 2025, indicating that the overdues have continued for several months. Across different parts of the information disclosed, the aggregate overdue is described as roughly ₹15.57 crore to ₹15.58 crore. The company has stated it is making arrangements to clear the overdue amounts as soon as possible, without providing a specific timeline.

What Mangalam Drugs reported to the exchanges

In its subsequent intimation, Mangalam Drugs said it had defaulted on cash credit loan accounts with two banks. The filing lists the overdue amount for Bank of Maharashtra at INR 95.119 million and for Bank of Baroda at INR 60.608 million. In rupee terms commonly used in Indian market disclosures, these are approximately ₹9.51 crore and ₹6.06 crore, respectively. Taken together, they add up to about ₹15.57 crore. The company’s disclosure also provides specific loan account numbers for both facilities. Such intimation is typically used by listed companies to keep investors informed about continuing defaults once the reporting threshold has been crossed.

Bank-wise breakup of the overdue dues

For Bank of Maharashtra, the company disclosed an overdue amount of INR 95.119 million on a cash credit account (Cash Credit A/c No: 60383561246). The filing states that the default on this facility commenced on October 17, 2025. For Bank of Baroda, the disclosed overdue is INR 60.608 million on a cash credit account (Cash Credit A/c No: 04170500000243). The default start date for this facility is October 20, 2025. The figures have been described in multiple parts of the disclosed material, and the combined overdue is consistently indicated at around ₹15.57 crore to ₹15.58 crore based on those numbers.

When the defaults began and why dates matter

The disclosures place the beginning of the default period in mid-October 2025 for both banks, and the company said the defaults have continued beyond 30 days. This detail is material because SEBI’s disclosure framework for listed entities focuses on timely reporting once an obligation remains unpaid beyond a defined period. The company’s filings also mention different “as of” dates for the overdue amounts in the narrative, including references such as June 15, 2026 and July 15, 2026 in the context provided. Regardless of the specific cut-off date used in each update, the amounts and default start dates indicate continuing stress on these working capital facilities. Since cash credit is typically linked to day-to-day working capital needs, persistent overdues can affect vendor cycles, inventory decisions, and lender monitoring.

Regulatory framework: why the company had to disclose

Mangalam Drugs said it made the disclosure under Regulation 30 of SEBI LODR, which requires listed companies to disclose material events. A default in payment of interest or principal on borrowings beyond 30 days is treated as a reportable event under exchange and SEBI disclosure practices. In practical terms, such disclosures aim to ensure investors receive uniform and time-bound information when a company’s repayment record changes. The filing described the default as exceeding 30 days, and it provided the bank names, facility type, amounts overdue, and the date from which default started.

Annual report context: FY2025-26 loss and other disclosures

Separately, Mangalam Drugs filed its FY2025-26 annual report on August 31, 2026, reporting a net loss of ₹4,381.42 lakh. The company attributed the loss to external funding disruptions in global health procurement, as described in the provided context. The annual report section cited in the context also states that the company had 99.99% of shares in dematerialized form. It added that there were no dividend recommendations. The same context mentions disclosure of loan defaults, including principal amounts and interest overdue of ₹12.54 lakh, though the principal total is flagged as having a mismatch in the provided text. Given the inconsistencies in the principal total presented in the context, the bank-wise overdue amounts from the default filing remain the cleanest comparable figures.

What this could mean for investors and lenders

For investors, the key takeaway is that the defaults relate to cash credit facilities and have continued for months after the initial October 2025 default dates. Such continuing overdues typically increase the importance of monitoring follow-up disclosures, lender actions, and any changes in working capital arrangements. For lenders, prolonged cash credit overdues can trigger tighter monitoring, revised drawing power calculations, or other remedial steps depending on facility terms and bank processes. The company has said it is arranging to clear the overdue dues, but it has not provided a defined repayment schedule in the material shared here. Investors will also likely track whether subsequent filings show reductions in overdue amounts or any restructuring steps.

Key data table from the default intimation

What to watch in future updates

The most relevant next data points will be any subsequent exchange filings that confirm repayment, partial regularisation, or changes in the overdue status. Investors typically also track whether overdue interest continues to accumulate, and whether the company provides more detail on the repayment plan it referenced. Since the annual report was filed on August 31, 2026 and includes a large FY2025-26 net loss, readers may also watch for any further commentary on liquidity, working capital management, and bank facilities in company communications.

Conclusion

Mangalam Drugs and Organics has disclosed continuing defaults on cash credit facilities with Bank of Maharashtra and Bank of Baroda, with overdue dues of about ₹15.57 crore and default start dates in October 2025. The company has said it is arranging to clear the overdue amounts, and future exchange updates will be the primary source for confirmation of any repayment progress.